<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974359</url>
  </required_header>
  <id_info>
    <org_study_id>19365A</org_study_id>
    <nct_id>NCT04974359</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia</brief_title>
  <official_title>Interventional, Randomized, Double-Blind, Crossover, Placebo-Controlled, Multiple-Dose Lu AG06466 Phase IB Study in Patients With Fibromyalgia Using Neuroimaging to Investigate Its Pharmacodynamic Effects on Central Pain Processing and Neuroinflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out the effect of Lu AG06466 on the body in participants&#xD;
      with fibromyalgia by assessing pain levels, brain signal changes, and psychiatric (mental)&#xD;
      assessments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will include 2 treatment periods and will utilize a crossover study design with a&#xD;
      7- to 14-day washout period between each 22-day treatment period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2021</start_date>
  <completion_date type="Anticipated">September 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Oxygene Level Dependent (BOLD) Response in the Evoked-Pain Test</measure>
    <time_frame>Day 22 of each 22-day treatment period</time_frame>
    <description>BOLD response was evaluated using Functional Magnetic Resonance Imaging (fMRI). During the evoked-pain test, each participant will undergo a block design scan, during which 3 cuff pressures ('light touch' = 30 millimeter of mercury [mmHg]; 'equal pressure' = 120 mmHg; 'equal pain' = 40 to 60/100 Numeric Rating Scale [NRS] units) will be applied to the left calf using the pressure cuff device in pseudo random order.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Resting State fMRI (rsfMRI) Functional Connectivity, Assessed by Voxelwise Connectivity Maps Based in Seed Voxels</measure>
    <time_frame>Day 22 of each 22-day treatment period</time_frame>
    <description>Each participant will undergo a task-free resting state scan, where in they will be instructed to focus on a static fixation cross.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fMRI Data: BOLD Percent Signal Change Under Conditions of Visual Stimulation Versus Fixation</measure>
    <time_frame>Day 22 of each 22-day treatment period</time_frame>
    <description>Each participant will undergo a block design scan, with alternating blocks of flashing checkerboard and a static fixation cross.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Lu AG06466</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive an oral titrated dose of Lu AG06466 once daily for 22 days in 1 of 2 treatment periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive an oral dose of placebo matching to Lu AG06466 once daily for 22 days in 1 of 2 treatment periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AG06466</intervention_name>
    <description>Lu AG06466 - capsules</description>
    <arm_group_label>Lu AG06466</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo - capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant has a body mass index (BMI) of ≥18.5 and ≤38.0 kilograms (kg)/square&#xD;
             meter (m^2).&#xD;
&#xD;
          -  The participant has a fibromyalgia diagnosis, with self-reported pain visual analogue&#xD;
             scale (VAS) score &gt;4, based on a self-reported pain diary assessed for a minimum of 4&#xD;
             out of 7 days prior to the Baseline Visit.&#xD;
&#xD;
          -  The participant is, in the opinion of the investigator, eligible based on medical&#xD;
             history, a physical examination, a neurological examination, vital signs (including&#xD;
             orthostatic vital signs), an electrocardiogram (ECG), and the results of the clinical&#xD;
             chemistry, hematology, urinalysis, serology, and other laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant has a disease, including clinically significant liver disease of any&#xD;
             origin, or takes medication that could, in the investigator's opinion, interfere with&#xD;
             the assessments of safety, tolerability, or efficacy, or interfere with the conduct or&#xD;
             interpretation of the study.&#xD;
&#xD;
          -  The participant has any other disorder for which the treatment takes priority over the&#xD;
             treatment of fibromyalgia in this study or is likely to interfere with the study&#xD;
             treatment or impair treatment compliance.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <phone>+45 36301311</phone>
    <email>LundbeckClinicalTrials@Lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Collaborative NeuroScience Network LLC</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>July 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

